JP2022505928A5 - - Google Patents

Info

Publication number
JP2022505928A5
JP2022505928A5 JP2021523014A JP2021523014A JP2022505928A5 JP 2022505928 A5 JP2022505928 A5 JP 2022505928A5 JP 2021523014 A JP2021523014 A JP 2021523014A JP 2021523014 A JP2021523014 A JP 2021523014A JP 2022505928 A5 JP2022505928 A5 JP 2022505928A5
Authority
JP
Japan
Prior art keywords
compound
nanoparticles
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021523014A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505928A (ja
JP7437051B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/057406 external-priority patent/WO2020086555A1/en
Publication of JP2022505928A publication Critical patent/JP2022505928A/ja
Publication of JP2022505928A5 publication Critical patent/JP2022505928A5/ja
Application granted granted Critical
Publication of JP7437051B2 publication Critical patent/JP7437051B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523014A 2018-10-22 2019-10-22 抗ウイルスプロドラッグおよびそのナノ製剤 Active JP7437051B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748798P 2018-10-22 2018-10-22
US62/748,798 2018-10-22
PCT/US2019/057406 WO2020086555A1 (en) 2018-10-22 2019-10-22 Antiviral prodrugs and nanoformulations thereof

Publications (3)

Publication Number Publication Date
JP2022505928A JP2022505928A (ja) 2022-01-14
JP2022505928A5 true JP2022505928A5 (cg-RX-API-DMAC7.html) 2022-11-09
JP7437051B2 JP7437051B2 (ja) 2024-02-22

Family

ID=70331730

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523014A Active JP7437051B2 (ja) 2018-10-22 2019-10-22 抗ウイルスプロドラッグおよびそのナノ製剤

Country Status (18)

Country Link
US (5) US11154557B2 (cg-RX-API-DMAC7.html)
EP (4) EP4751717A3 (cg-RX-API-DMAC7.html)
JP (1) JP7437051B2 (cg-RX-API-DMAC7.html)
KR (2) KR102908976B1 (cg-RX-API-DMAC7.html)
CN (2) CN116375735B (cg-RX-API-DMAC7.html)
AU (2) AU2019368247B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021007622A2 (cg-RX-API-DMAC7.html)
CA (2) CA3117453A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190974A1 (cg-RX-API-DMAC7.html)
ES (2) ES2970251T3 (cg-RX-API-DMAC7.html)
IL (2) IL282551B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021004679A (cg-RX-API-DMAC7.html)
MY (1) MY207622A (cg-RX-API-DMAC7.html)
PH (1) PH12021550905A1 (cg-RX-API-DMAC7.html)
SA (1) SA521421845B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202104117WA (cg-RX-API-DMAC7.html)
WO (1) WO2020086555A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA202102846B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4751717A3 (en) 2018-10-22 2026-08-05 Board of Regents of the University of Nebraska Antiviral prodrugs and nanoformulations thereof
CN118873676A (zh) 2018-11-29 2024-11-01 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
KR20240151256A (ko) 2019-03-22 2024-10-17 길리애드 사이언시즈, 인코포레이티드 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
EP4110783A1 (en) 2020-02-24 2023-01-04 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
CN116390924B (zh) 2020-09-30 2025-11-07 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其用途
CR20260070A (es) 2021-01-19 2026-04-24 Gilead Sciences Inc COMPUESTOS DE PIRIDOTRIAZINA SUSTITUIDOS Y USOS DE ESTOS (Divisional 2023-0315)
WO2023183472A1 (en) * 2022-03-23 2023-09-28 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and use thereof
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
CN120936599A (zh) * 2023-01-18 2025-11-11 歌礼生物科技(杭州)有限公司 整合酶抑制剂及其应用
CN121194783A (zh) * 2023-03-17 2025-12-23 依沙维治疗公司 抗病毒前药的制剂
WO2024196661A1 (en) * 2023-03-17 2024-09-26 Exavir Therapeutics, Inc. Crystalline forms of an antiviral prodrug
WO2024227037A1 (en) * 2023-04-26 2024-10-31 University Of Washington Long-acting colloidal pharmaceutical compositions of integrase strand transfer inhibitors and related methods
WO2025011661A1 (zh) * 2023-07-12 2025-01-16 歌礼生物科技(杭州)有限公司 整合酶抑制类的制剂及其制备方法
TW202543636A (zh) 2023-12-12 2025-11-16 美商 Viiv 醫療保健公司 結晶形式
WO2025128498A1 (en) * 2023-12-12 2025-06-19 Viiv Healthcare Company Pharmaceutical compositions
WO2026012272A1 (en) * 2024-07-12 2026-01-15 Ascletis Bioscience Co., Ltd. Integrase inhibitor and use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3187225T3 (da) * 2005-04-28 2022-02-28 Viiv Healthcare Co Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet
EP2660239B1 (en) * 2008-07-25 2016-11-23 VIIV Healthcare Company Chemical compounds as synthetic intermediates
SMT202100268T1 (it) * 2010-08-05 2021-07-12 Shionogi & Co Metodo per produrre composti aventi attività di inibizione di integrasi di hiv.
TWI577377B (zh) * 2010-09-16 2017-04-11 Viiv醫療保健公司 醫藥組合物
LT2620436T (lt) * 2010-09-24 2018-08-10 Shionogi & Co., Ltd. Pakeistojo policiklinio karbamoilpiridono darinio provaistas
JP2013542945A (ja) 2010-11-02 2013-11-28 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 治療を送達するための組成物および方法
WO2014047562A2 (en) * 2012-09-21 2014-03-27 Epiphany Biosciences Method of treating and/or preventing shingles and method of treating and/or preventing zoster associated pain
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
EA030003B1 (ru) * 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
HK1214817A1 (en) * 2012-12-27 2016-08-05 Japan Tobacco Inc. Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as hiv integrase inhibitor
US9951079B2 (en) 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
EA201690146A1 (ru) 2013-08-14 2016-07-29 Ратиофарм Гмбх Лекарственное средство, содержащее фармацевтическую комбинацию долутегравира, эмтрицитабина и тенофовира
CN117164657A (zh) * 2014-08-12 2023-12-05 莫纳什大学 定向淋巴的前药
US10081647B2 (en) * 2015-03-26 2018-09-25 Merck Sharp & Dohme Corp. Phosphate substituted quinolizine derivatives useful as HIV integrase inhibitors
EP3334722A1 (en) * 2015-08-12 2018-06-20 VIIV Healthcare UK (No.5) Limited 5-(n-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3- yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2017113288A1 (en) * 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
JP7160466B2 (ja) 2016-06-23 2022-10-25 ヴィーブ ヘルスケア カンパニー 治療薬の送達のための組成物及び方法
LT3347352T (lt) * 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
AR112412A1 (es) * 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
EP4751717A3 (en) 2018-10-22 2026-08-05 Board of Regents of the University of Nebraska Antiviral prodrugs and nanoformulations thereof
CN118873676A (zh) 2018-11-29 2024-11-01 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
MX2023005447A (es) 2020-11-10 2023-09-25 Unity Biotechnology Inc Inhibidor de sales sólidas cristalinas de meglumina de bcl y métodos de elaboración y uso de estos.

Similar Documents

Publication Publication Date Title
IL282551B1 (en) Antiviral prodrugs and their nanoformulations
JP2020097577A5 (cg-RX-API-DMAC7.html)
JP2024516371A5 (cg-RX-API-DMAC7.html)
JP2020505423A5 (cg-RX-API-DMAC7.html)
RU2013121788A (ru) Ингибиторы репликации вич
JP2019524670A5 (cg-RX-API-DMAC7.html)
HRP20161280T1 (hr) Farmaceutski pripravci
JP2018138578A5 (cg-RX-API-DMAC7.html)
JP2019516739A5 (cg-RX-API-DMAC7.html)
IL273177B2 (en) Fluorophenyl beta-hydroxyethylamines and their uses in the treatment of hyperglycemia
JP2019529541A5 (cg-RX-API-DMAC7.html)
JP2022525013A5 (cg-RX-API-DMAC7.html)
RU2015149527A (ru) Производные доластатина 10 и ауристатинов
JP2016510041A5 (cg-RX-API-DMAC7.html)
SI2945620T1 (en) Nitroxyl donors with improved therapeutic index
RU2018140900A (ru) Семаглутид при сердечно-сосудистых состояниях
JP2010505865A5 (cg-RX-API-DMAC7.html)
CL2021001018A1 (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
JP2011046708A5 (cg-RX-API-DMAC7.html)
JP2022531251A5 (cg-RX-API-DMAC7.html)
JP2015512420A5 (cg-RX-API-DMAC7.html)
JP2023537921A5 (cg-RX-API-DMAC7.html)
JP2022551691A5 (cg-RX-API-DMAC7.html)
JP2015516419A5 (cg-RX-API-DMAC7.html)